Les traitements en cours de développement dans l’arthrose

The pharmalogical therapies currently available for the management of osteoarthritis are limited, either because of they have a modest effect-size, or because they can expose elder patients with often multiple comorbidities to a substantial risk of potentially dangerous side effects. The prevalence of osteoarthritis increases consistently, and there is therefore a major need for new treatments to treat the symptoms of osteoarthritis, but also to slow or stop the progression of the disease. The better understanding of the pathophysiology of osteoarthritis has led to the identification of new therapeutic targets, and some drugs related to these targets are currently being studied in phase 2 or 3 randomized controlled trials. These include anti-NGF antibodies, sprifermin, Wnt or cathepsin K inhibitors, some of which have shown promising results. Their long-term tolerance profile remains to be determined. Also, the benefit:risk ratio of anti-NGF antibodies, which induce rapidly progressive arthropathies, remains to be determined. These new treatments could, however, offer new therapeutic prospects for patients in the coming years.